Kymera Therapeutics
KYMR
108.35
+2.37
+2.24%
Kymera Therapeutics
US · KYMR
#1580 by market cap
Listed 2020
108.35
+2.37
+2.24%
Live - 5344 symbols - heartbeat 161s ago
· 2026-10-08 04:01
Pre-market
108.35
0.00%
After-hours
106.00
-2.17%
- Market cap
- 9.01B
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KYMR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 32.19, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -16.70% YoY
Margins
- Operating margin
- -881.24%
- Net margin
- -794.04%
Key ratios & quality
- Altman Z-Scorei
- 32.19
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M | 39.21M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.77M | 7.98M | 18.23M | 36.35M | 43.83M | 55.04M | 63.53M | 68.19M |
| Research & development | 17.68M | 37.16M | 62.11M | 137.02M | 164.25M | 189.08M | 240.25M | 316.57M |
| Operating profit | -21.45M | -42.21M | -46.30M | -100.53M | -161.26M | -165.53M | -256.71M | -345.54M |
| Pretax profit | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.35M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.35M |
| Basic EPS | -1 | -1 | -3 | -2 | -3 | -3 | -3 | -4 |
| Diluted EPS | -1.07 | -1.37 | -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 22.10M | 11.48M | 2.76M | 2.87M | 34.37M | 65.00M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 16.27M | 17.65M | 17.34M | 16.94M | 20.36M | 21.13M |
| Research & development | 80.26M | 78.39M | 74.09M | 83.83M | 98.16M | 119.48M |
| Operating profit | -74.43M | -84.56M | -88.67M | -97.90M | -84.15M | -75.61M |
| Pretax profit | -65.58M | -76.61M | -82.18M | -86.98M | -69.23M | -61.21M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -65.58M | -76.61M | -82.18M | -86.98M | -69.23M | -61.21M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.82 | -0.95 | -0.94 | -0.97 | -0.71 | -0.62 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 41.79M | 92.85M | 302.34M | 451.27M | 419.42M | 405.32M | 510.27M | 871.21M |
| Cash & ST investments | 41.26M | 91.96M | 296.20M | 442.42M | 407.17M | 374.88M | 488.74M | 848.28M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 44.23M | 116.70M | 487.18M | 605.91M | 603.13M | 575.76M | 978.04M | 1.74B |
| Total current liabilities | 4.69M | 34.57M | 110.62M | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M |
| Short-term debt | 302.00K | 3.38M | 3.26M | 3.60M | 3.94M | 6.35M | 13.11M | 13.76M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 78,667,000.00 | 191,108,000.00 | 203,287,000.00 | 146,267,000.00 | 112,983,000.00 | 180,788,000.00 | 142,416,000.00 | 163,148,000.00 |
| Total equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B |
| Retained earnings | -35.21M | -76.46M | -128.77M | -228.98M | -383.79M | -530.75M | -754.61M | -1.07B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 500.95M | 728.33M | 528.30M | 871.21M | 677.43M | 737.27M |
| Cash & ST investments | 463.15M | 665.45M | 505.68M | 848.28M | 650.93M | 690.99M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 918.31M | 1.13B | 1.10B | 1.74B | 1.67B | 1.65B |
| Total current liabilities | 58.99M | 87.54M | 71.58M | 83.21M | 62.64M | 71.33M |
| Short-term debt | 13.24M | 13.67M | 13.74M | 13.76M | 13.73M | 13.70M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 132,079,000.00 | 159,588,000.00 | 155,786,000.00 | 163,148,000.00 | 129,379,000.00 | 136,188,000.00 |
| Total equity | 786.23M | 971.48M | 946.26M | 1.58B | 1.54B | 1.51B |
| Retained earnings | -820.19M | -896.81M | -978.98M | -1.07B | -1.14B | -1.20B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -17.86M | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M | -194.50M | -232.89M |
| Depreciation & amortization | 205.00K | 825.00K | 1.76M | 2.40M | 2.98M | 3.57M | 7.37M | 8.31M |
| Free cash flow | -19.22M | 17.37M | 79.03M | -130.54M | -155.92M | -137.31M | -207.34M | -234.34M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 196.67M | 243.11M | 149.83M | 0 | 596.62M | 928.90M |
| Ending cash balance | 41.46M | 77.79M | 32.59M | 54.09M | 74.53M | 115.78M | 126.05M | 362.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -79.15M | -59.88M | -27.11M | -66.75M | -88.84M | -54.07M |
| Depreciation & amortization | 2.05M | 2.08M | 2.15M | 2.03M | 2.02M | 2.03M |
| Free cash flow | -79.62M | -60.58M | -27.29M | -66.85M | -89.27M | -54.54M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 35.38M | 656.23M | -- | -- |
| Ending cash balance | 95.77M | 341.64M | 118.74M | 362.81M | 149.90M | 130.30M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -52.17 | -26.96 | -32.60 | -33.21 | -36.38 | -25.78 |
| ROA %i | -48.53 | -51.26 | -18.10 | -18.34 | -25.61 | -24.93 | -28.81 | -22.89 |
| ROIC %i | -- | -- | -44.52 | -25.79 | -32.74 | -33.54 | -37.30 | -27.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -36.26 | -30.99 |
| EBIT margin %i | -- | -1,404.23 | -133.63 | -137.36 | -330.23 | -186.74 | -475.04 | -793.10 |
| FCF / sales %i | -- | 592.13 | 232.22 | -- | -- | -- | -- | -- |
| Current ratioi | 8.92 | 2.69 | 2.73 | 4.88 | 5.88 | 4.73 | 7.53 | 10.47 |
| Quick ratioi | 8.83 | 2.66 | 2.69 | 4.78 | 5.74 | 4.59 | 7.21 | 10.19 |
| Debt / assetsi | 1.57 | 18.16 | 3.69 | 2.96 | 2.87 | 14.71 | 8.97 | 4.72 |
| LT debt / equityi | -- | -- | 5.19 | 3.13 | 2.73 | 19.83 | 8.93 | 4.34 |
| Interest coveragei | -1,340.69 | -895.65 | -395.46 | -571.67 | -878.59 | -748.81 | -898.03 | -840.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 151.77 | 32.18 | -13.54 | -5.74 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -32.17 | -33.26 | -32.09 | -25.78 | -27.09 | -24.15 |
| ROA %i | -26.97 | -28.15 | -27.62 | -22.89 | -24.35 | -21.58 |
| ROIC %i | -33.31 | -34.08 | -33.04 | -27.03 | -28.81 | -26.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -408.64 | -615.37 | -674.02 | -793.10 | -611.25 | -285.02 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.49 | 8.32 | 7.38 | 10.47 | 10.81 | 10.34 |
| Quick ratioi | 8.19 | 8.06 | 7.07 | 10.19 | 10.39 | 9.97 |
| Debt / assetsi | 9.40 | 7.58 | 7.62 | 4.72 | 4.82 | 4.77 |
| LT debt / equityi | 9.30 | 7.42 | 7.42 | 4.34 | 4.33 | 4.30 |
| Interest coveragei | -954.88 | -923.28 | -869.57 | -840.49 | -876.45 | -904.14 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Dedicated to reinventing the treatment of human disease through the development of innovative100.00%
Quote time 2026-10-08 04:01:21 · For reference only, not investment advice and not tailored to your situation.